← Leaderboards
Albert Koong
University Of Tx Md Anderson Can Ctr
$7,304,561
Attributed
$8,936,242
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,296,108 · 11
By mechanism
U54$6,523,836 · 3
R01$5,388,792 · 5
P01$2,303,228 · 2
P30$80,252 · 1
Top collaborators
- Quynh-Thu X Le5 shared
- Boyi Gan4 shared
- Constantinos Koumenis4 shared
- Dadi Jiang1 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Cullen Mitsuo Taniguchi$3,293,212
- Sam Beddar$2,871,036
- Jerimy C. Polf$1,927,458
- Zhongxing Liao$4,193,578
- Boyi Gan$13,125,533
Others in their field
Top investigators on “Hypoxia”
- James B Edson · Woods Hole Oceanographic Institution$110,367,520
- Albert J Plueddemann · Woods Hole Oceanographic Institution$110,367,520
- David Heimbrook · Leidos Biomedical Research, Inc.$41,862,534
- Nanduri R Prabhakar · Case Western Reserve University$32,967,177
- Zaver M Bhujwalla · Johns Hopkins University$30,055,665
- Donna M. Ferriero · University Of California, San Francisco$27,259,560
Research focus
HypoxiaTumorResponseTumor GrowthMalignant NeoplasmsMediatingPathway InteractionsProteinsNeoplastic CellCellsRadiationRadiation TherapyBaseIn VivoChemotherapyToxic EffectImageMalignant Neoplasm Of PancreasMalignant Neoplasm Of LungEffectivenessMonitorPre-ClinicalFamilyMember
Grant awards (40)
Acquired Resistance to Therapy and Iron (ARTI) Center$1,356,911
U54 · FY2025 · CA
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma$572,667
R01 · FY2025 · CA · contact PI
Tumor hypoxia promotes acquired resistance to radiation through ferroptosis inhibition$288,757
U54 · FY2025 · CA · contact PI
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma$37,001
R01 · FY2025 · CA · contact PI
Acquired Resistance to Therapy and Iron (ARTI) Center$1,289,134
U54 · FY2024 · CA
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma$544,035
R01 · FY2024 · CA · contact PI
Tumor hypoxia promotes acquired resistance to radiation through ferroptosis inhibition$275,188
U54 · FY2024 · CA · contact PI
Acquired Resistance to Therapy and Iron (ARTI) Center$1,356,931
U54 · FY2023 · CA
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer$370,985
R01 · FY2023 · CA · contact PI
Tumor hypoxia promotes acquired resistance to radiation through ferroptosis inhibition$288,757
U54 · FY2023 · CA · contact PI
Acquired Resistance to Therapy and Iron (ARTI) Center$1,356,890
U54 · FY2022 · CA
Tumor hypoxia promotes acquired resistance to radiation through ferroptosis inhibition$311,268
U54 · FY2022 · CA · contact PI
29 Radiation Oncology and Cancer Imaging$18,707
P30 · FY2022 · CA · contact PI
29 Radiation Oncology and Cancer Imaging$18,707
P30 · FY2021 · CA · contact PI
29 Radiation Oncology and Cancer Imaging$18,676
P30 · FY2020 · CA · contact PI
29 Radiation Oncology and Cancer Imaging$18,707
P30 · FY2019 · CA · contact PI
29 Radiation Oncology and Cancer Imaging$5,455
P30 · FY2019 · CA · contact PI
The Role of Ire1 in Modulating the Response of Tumors to Hypoxia and Radiation$204,282
P01 · FY2017 · CA · contact PI
Targeting Galectin-1 with radiation in lung cancer$326,986
R01 · FY2016 · CA
The Role of Ire1 in Modulating the Response of Tumors to Hypoxia and Radiation$204,282
P01 · FY2016 · CA · contact PI
Targeting Galectin-1 with radiation in lung cancer$326,940
R01 · FY2015 · CA
The Role of Ire1 in Modulating the Response of Tumors to Hypoxia and Radiation$204,282
P01 · FY2015 · CA · contact PI
Targeting Galectin-1 with radiation in lung cancer$317,077
R01 · FY2014 · CA
The Role of Ire1 in Modulating the Response of Tumors to Hypoxia and Radiation$198,153
P01 · FY2014 · CA · contact PI
Targeting Galectin-1 with radiation in lung cancer$307,201
R01 · FY2013 · CA
The Role of Ire1 in Modulating the Response of Tumors to Hypoxia and Radiation$204,282
P01 · FY2013 · CA · contact PI
Targeting Galectin-1 with radiation in lung cancer$326,810
R01 · FY2012 · CA
Pharmacological targeting of the Unfolded Protein Response as an antitumor strate$320,887
R01 · FY2012 · CA
Pharmacological targeting of the Unfolded Protein Response as an antitumor strate$330,267
R01 · FY2011 · CA
Pharmacologic /Genetic Inhibition of XBP1 as Hypoxia Targeted Therapeutic Strateg$246,206
P01 · FY2011 · CA · contact PI
Pharmacological targeting of the Unfolded Protein Response as an antitumor strate$350,444
R01 · FY2010 · CA
Pharmacologic /Genetic Inhibition of XBP1 as Hypoxia Targeted Therapeutic Strateg$266,097
P01 · FY2010 · CA · contact PI
Pharmacological targeting of the Unfolded Protein Response as an antitumor strate$345,483
R01 · FY2009 · CA
Pharmacologic /Genetic Inhibition of XBP1 as Hypoxia Targeted Therapeutic Strateg$263,139
P01 · FY2009 · CA · contact PI
Pharmacologic /Genetic Inhibition of XBP1 as Hypoxia Targeted Therapeutic Strateg$257,733
P01 · FY2008 · CA · contact PI
The Role of XBP1 During Hypoxia and Tumor Growth$223,293
R01 · FY2008 · CA · contact PI
Pharmacologic /Genetic Inhibition of XBP1 as Hypoxia Targeted Therapeutic Strateg$254,772
P01 · FY2007 · CA · contact PI
The Role of XBP1 During Hypoxia and Tumor Growth$223,267
R01 · FY2007 · CA · contact PI
The Role of XBP1 During Hypoxia and Tumor Growth$229,909
R01 · FY2006 · CA · contact PI
The Role of XBP1 During Hypoxia and Tumor Growth$235,540
R01 · FY2005 · CA